Can Lithium Prevent Alzheimer's? What a Harvard Study Published in Nature Found

Alzheimer's disease is on a steep upward curve. Domestic projections estimate that the number of diagnosed patients will surpass one million within the next year, with that figure expected to double within two decades. Against that backdrop, a recent study published in the journal Nature—the result of ten years of research at Harvard University—has attracted significant attention from scientists and clinicians alike.

The finding: when lithium levels in the brain drop too low, it may trigger the onset of memory decline and Alzheimer's-type dementia. Conversely, restoring those levels appears to preserve brain function. Here's a closer look at what the research actually showed, how lithium works in the brain, and what the findings do and don't mean for the average person.

What Is Lithium, and Why Does the Brain Care About It?

Most people associate lithium with psychiatric medication, and that association is accurate. Lithium has been used in psychiatry for decades—primarily for bipolar disorder, but also for depression. It acts on cell membranes by regulating membrane potential, which in turn stabilizes the release of various neurotransmitters. In bipolar disorder, it helps quiet an overactive dopamine system during manic episodes. In depression, it can boost serotonin activity. There is also established research linking higher lithium levels in public water supplies to lower suicide rates across multiple countries.

But lithium isn't only a pharmaceutical compound. It's also a trace element naturally present in many foods, absorbed through the diet in small amounts. The brain has always relied on lithium at these trace levels to perform a range of regulatory functions—a fact that makes the Harvard findings all the more significant.

What the Harvard Study Found

Researchers divided subjects into three groups: cognitively healthy individuals, those with mild memory decline, and those with Alzheimer's-level cognitive impairment. They then tested for deficiencies in 27 different trace metal elements across these groups to identify which ones, if any, were consistently depleted in people with declining cognition.

The result was striking in its specificity. Out of 27 elements tested, only one was consistently deficient in subjects with memory loss and Alzheimer's disease: lithium.

To test whether this deficiency was causal rather than coincidental, researchers turned to animal models. Mice were placed on a low-lithium diet, which caused brain lithium levels to fall faster than normal. As those levels dropped, the mice showed measurable memory decline along with increased neuroinflammation.

The connection to existing Alzheimer's research became clearer from there. Amyloid beta plaques—long considered the primary pathological hallmark of Alzheimer's—were found to contain significant concentrations of lithium. When mice were deprived of lithium, amyloid beta plaque formation accelerated. And as plaques accumulated, they appeared to sequester even more lithium, creating a self-reinforcing cycle: lower lithium leads to more plaque, and more plaque leads to less available lithium.

Tau protein tangles, another key marker of Alzheimer's pathology, also progressed more rapidly in lithium-deficient conditions.

Lithium Orotate vs. Lithium Carbonate: Why the Form Matters

Researchers then tested whether lithium supplementation could reverse the damage in affected mice. They compared two compounds: lithium carbonate, the standard pharmaceutical form used in psychiatric practice, and lithium orotate, a compound that combines lithium with orotic acid and is more commonly found in nutritional supplements.

The results were unexpected. Lithium carbonate showed little to no effect on amyloid plaque formation. Lithium orotate, by contrast, significantly reduced plaque buildup, restored brain function, and improved memory—even in older mice with advanced disease progression.

The difference comes down to how each compound crosses the blood-brain barrier.

Lithium carbonate dissociates in the body, releasing lithium as a free ion. In that ionic state, lithium has two problems getting into the brain efficiently. First, free lithium ions carry a positive charge, while amyloid plaques carry a negative charge—meaning the ions are actively attracted to plaques and get trapped before reaching their target. Second, free ions are small enough to fit into the molecular gaps within plaques, making them even more susceptible to being sequestered.

Lithium orotate, on the other hand, stays bonded to orotic acid as it travels through the body. Orotic acid has dedicated transporters that carry it into the brain. When lithium is attached to orotic acid, it essentially hitchhikes through those transporters. The bond also masks lithium's positive charge and increases its molecular size, both of which reduce the likelihood of it being captured by negatively charged amyloid plaques before it can reach its target.

Once inside the brain, lithium—in either form—inhibits an enzyme called GSK3β (glycogen synthase kinase 3 beta), which plays a key role in amyloid beta production and plaque formation. By suppressing this enzyme, lithium may interrupt the molecular cascade that leads to Alzheimer's disease.

The study also found that maintaining stable lithium levels from an early age could potentially prevent Alzheimer's from developing in the first place—at least in the animal model.

What This Means—and What It Doesn't

Before drawing any practical conclusions, it's essential to understand the current limits of this research. The study's own authors explicitly stated that lithium has not yet been proven safe or effective for preventing neurodegeneration in humans and that people should not begin taking lithium compounds on their own based on this data.

That's not just standard scientific caution—it reflects genuine clinical risk.

Lithium carbonate, the pharmaceutical form, has a well-documented safety profile built up over decades of clinical use. Doctors know its therapeutic range, its side effects, and how to monitor patients on it. But that therapeutic range is unusually narrow. The gap between a therapeutic dose and a toxic dose is smaller than with most medications.

Lithium orotate, the supplement form highlighted by this study, does not yet have the same depth of clinical data. The optimal dose, the duration of use required for a meaningful effect, and the long-term safety profile in humans are all still unknown.

Toxicity from lithium overdose is serious and can include movement disorders, slurred speech, loss of coordination, and—at higher concentrations—loss of consciousness and coma. Dehydration is a particular risk factor: even at a normal dose, lithium concentration in the blood rises when the body loses fluids, which can unexpectedly push levels into a toxic range. Kidney toxicity and thyroid toxicity are also documented concerns with long-term lithium use, making regular monitoring of kidney and thyroid function essential for people taking the pharmaceutical form. Lithium is also contraindicated during pregnancy.

Why This Research Still Matters

Developing drugs that act on the central nervous system is notoriously difficult. The blood-brain barrier blocks most compounds. Clinical trials take years. And many major pharmaceutical companies have scaled back investment in CNS drug development in recent years because the failure rate has been too high relative to the cost.

That retreat from CNS research means fewer breakthroughs for the people who need them most—those living with dementia, psychiatric illness, and other brain diseases. In that context, a finding that a trace element already present in the human body may have a protective role in Alzheimer's prevention is genuinely exciting, even if the full clinical picture remains to be established.

The hope is that research like this can help shift the field's understanding of Alzheimer's pathology and open new avenues for prevention—ideally before the demographic wave of aging populations makes the crisis even harder to manage.

Key Takeaways

• A Harvard study published in Nature found that lithium was the only trace element consistently depleted in people with Alzheimer's disease out of 27 elements tested.
• In animal models, low lithium levels accelerated amyloid beta plaque formation and tau protein tangles—two hallmarks of Alzheimer's pathology.
• Lithium orotate outperformed lithium carbonate in the study because it crosses the blood-brain barrier more effectively, aided by orotic acid transporters.
• Both forms of lithium appear to suppress GSK3β, an enzyme that promotes amyloid plaque formation.
• The research is not a basis for self-supplementation. Lithium has a narrow therapeutic window, real toxicity risks, and the clinical evidence for lithium orotate in humans has not yet been established.
• This study represents a potentially significant step toward better understanding Alzheimer's prevention, but human clinical trials are the necessary next step before any recommendations can be made.